Bio-Techne Corporation (TECH)

NASDAQ: TECH · IEX Real-Time Price · USD
70.39
+0.97 (1.40%)
At close: Mar 28, 2024, 4:00 PM
67.20
-3.19 (-4.53%)
After-hours: Mar 28, 2024, 5:39 PM EDT

Company Description

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.

The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids.

The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications.

The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014.

Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Bio-Techne Corporation
Bio-Techne logo
Country United States
Founded 1976
IPO Date Feb 9, 1989
Industry Biotechnology
Sector Healthcare
Employees 3,050
CEO Kim Kelderman

Contact Details

Address:
614 Mckinley Pl N E
Minneapolis, Minnesota 55413
United States
Phone (612) 379-8854
Website bio-techne.com

Stock Details

Ticker Symbol TECH
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0000842023
CUSIP Number 09073M104
ISIN Number US09073M1045
Employer ID 41-1427402
SIC Code 2836

Key Executives

Name Position
Kim Kelderman Chief Executive Officer, President and Director
James T. Hippel Executive Vice President of Finance and Chief Financial Officer
Shane Bohnen Senior Vice President, General Counsel and Corporate Secretary
Charles R. Kummeth Senior Advisor
William A. Geist President of Protein Sciences Segment
Dr. Gary J. Latham Ph.D. Vice President and Chief Technology Officer
David Clair Senior Director of Investor Relations and Corporate Development
Gerry Andros Vice President of Sales and Marketing
Robert M. Gavin Vice President of Corporate Development
Brenda S. Everson Senior Vice President and Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Mar 7, 2024 144 Filing
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 10-Q Quarterly Report
Feb 1, 2024 8-K Current Report
Jan 24, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 8, 2024 8-K Current Report
Nov 7, 2023 10-Q Quarterly Report
Oct 31, 2023 8-K Current Report
Oct 19, 2023 8-K Current Report
Sep 13, 2023 ARS Filing